Form 8-K - Current report:
SEC Accession No. 0001683168-24-006763
Filing Date
2024-09-30
Accepted
2024-09-30 16:30:08
Documents
17
Period of Report
2024-09-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K coeptis_8k.htm   iXBRL 8-K 34939
2 LETTER OF TURNER, STONE & COMPANY, LLP DATED SEPTEMBER 30, 2024 coeptis_ex1601.htm EX-16.1 3150
7 GRAPHIC image_004.jpg GRAPHIC 8386
8 GRAPHIC image_005.jpg GRAPHIC 11310
  Complete submission text file 0001683168-24-006763.txt   290833

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE coep-20240930.xsd EX-101.SCH 3263
4 XBRL DEFINITION FILE coep-20240930_def.xml EX-101.DEF 29964
5 XBRL LABEL FILE coep-20240930_lab.xml EX-101.LAB 36481
6 XBRL PRESENTATION FILE coep-20240930_pre.xml EX-101.PRE 26987
19 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5580
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 241339859
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)